A Phase 2 clinical trial evaluating buloxibutid, related to angiotensin II, updated its status as of October 29, 2026. The study, titled "A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis," is registered under identifier NCT06588686.
According to the registry listing, the trial's current status is active but not recruiting. This means enrollment has closed while the study continues to follow participants already enrolled. The trial is designed to assess both efficacy and safety outcomes in people with idiopathic pulmonary fibrosis.
No results have been posted for this trial as of the date noted. The listed phase is Phase 2, and no additional details about findings, timelines for completion, or further outcomes are included in this update. This brief reflects only the status change recorded in the trial registry and does not characterize or predict the study's eventual results.
Readers interested in background on angiotensin II, including its approved regulatory status and general context, can consult the compound overview for further information.